Stock Research: Collegium Pharmaceutical

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Collegium Pharmaceutical

NasdaqGS:COLL US19459J1043
35
  • Value
    20
  • Growth
    27
  • Safety
    Safety
    58
  • Combined
    6
  • Sentiment
    82
  • 360° View
    360° View
    35
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Collegium Pharmaceutical, Inc. is a biopharmaceutical company focused on products for ADHD and moderate to severe pain. It operates in the biopharmaceutical industry, with commercial products including Jornay PM, Belbuca, Xtampza ER, Nucynta ER and Nucynta IR, and Symproic, primarily in the United States. In the last fiscal year, the company had a market cap of $1,030 million, profits of $377 million, revenue of $631 million, and 357 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 35 (better than 35% compared with alternatives), overall professional sentiment and financial characteristics for the stock Collegium Pharmaceutical are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for Collegium Pharmaceutical. The consolidated Value Rank has an attractive rank of 58, which means that the share price of Collegium Pharmaceutical is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 58% of alternative stocks in the same industry. The consolidated Sentiment Rank has a good rank of 82, which means that professional investors are more optimistic about the stock than for 82% of alternative investment opportunities. But the consolidated Growth Rank has a low rank of 27, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. The consolidated Safety Rank has a riskier rank of 20, meaning the company has a riskier financing structure than 80 comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
58 63 37 77
Growth
27 65 63 43
Safety
Safety
20 18 25 40
Sentiment
82 82 89 39
360° View
360° View
35 62 56 49
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
78 75 58 1
Opinions Change
77 50 50 50
Pro Holdings
n/a 88 85 100
Market Pulse
73 51 75 38
Sentiment
82 82 89 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
58 63 37 77
Growth
27 65 63 43
Safety Safety
20 18 25 40
Combined
6 35 22 58
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
97 96 71 100
Price vs. Earnings (P/E)
62 66 58 66
Price vs. Book (P/B)
20 23 6 44
Dividend Yield
1 1 1 1
Value
58 63 37 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
22 70 27 23
Profit Growth
44 100 100 98
Capital Growth
39 14 18 35
Stock Returns
53 45 77 49
Growth
27 65 63 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
9 12 15 36
Refinancing
29 10 27 31
Liquidity
61 61 59 71
Safety Safety
20 18 25 40

Similar Stocks

Discover high‑ranked alternatives to Collegium Pharmaceutical and broaden your portfolio horizons.

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.